Identification of various types of α2-HS glycoprotein in sera of patients with pancreatic cancer: Possible implication in resistance to protease treatment

Molecular Medicine Reports

Volumn 3, Issue 4, 2010, Pages 651-656

  Kuwamoto, Kana ^a   Takeda, Yuri ^a   Shirai, Akiko ^b   Nakagawa, Tsutomu ^a   Takeishi, Shunsaku ^c   Ihara, Shinji ^e   Miyamoto, Yasuhide ^d   Shinzaki, Shinichiro ^a   Ko, Jeong Heon ^f   Miyoshi, Eiji ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DS Pharma Biomedical Co Ltd Research and Development Department   (Japan)

^c GPBio Science Corp   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^e DUKE UNIVERSITY   (United States)

^f Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

2 HS glycoprotein; Heterogeneity; Lectin array; Pancreatic cancer; Proteolysis

Indexed keywords

ALPHA2 HEREMANS SCHMID GLYCOPROTEIN; CHYMOTRYPSIN; FETUIN; HAPTOGLOBIN; LECTIN; OLIGOSACCHARIDE; PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CALCIFICATION; CANCER PATIENT; CANCER RESISTANCE; GEL CHROMATOGRAPHY; HUMAN; INSULIN RESISTANCE; LIVER; MASS SPECTROMETRY; MICROARRAY ANALYSIS; NONHUMAN; PANCREAS CANCER; PROTEIN ANALYSIS; PROTEIN BINDING; PURIFICATION; SERUM; VOLUNTEER;

EID: 77956709795     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr-00000311     Document Type: Article

References (32)

1. Dziegielewska KM, Brown WM, Casey SJ, Christie DL, Foreman RC, Hill RM, Saunders NR: The complete cDNA and amino acid sequence of bovine fetuin. J Biol Chem 265: 4354-4357, 1990.
2. Denecke B, Gräber S, Schäfer C, Heiss A, Wöltje M and Jahnen-Dechent W: Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J 376: 135-145, 2003. (Pubitemid 37487209)
3. Yoshioka Y, Gejyo F, Marti T, Rickli EE, Bürgi W, Offner GD, Troxler RF and Schmid K: The complete amino acid sequence of the A-chain of human plasma alpha 2 HS-glycoprotein. J Biol Chem 261: 1665-1676, 1986. (Pubitemid 17204999)
4. Gejyo F, Chang JL, Bürgi W, Schmid K, Offner GD, Troxler RF, van Halbeek H, Dorland L, Gerwig GJ and Vliegenthart JF: Characterization of the B-chain of human plasma alpha 2HS-glycoprotein. The complete amino acid sequence and primary structure of its heteroglycan. J Biol Chem 258: 4966-4971, 1983.
5. Kellermann J, Haupt H, Auerswald EA and Müller-Esterl W: The arrangement of disulfide loops in human alpha 2-HS glycoprotein. Similarity to the disulfide bridge structures of cystatins and kininogens. J Biol Chem 264: 14121-14128, 1989. (Pubitemid 19214240)
6. Nawratil P, Lenzen S, Kellermann J, Haupt H, Schinke T, Müller-Esterl W and Jahnen-Dechent W: Limited proteolysis of human α2-HS glycoprotein/fetuin. J Biol Chem 271: 31735-31741, 1996.
7. Hayase T, Rice KG, Dziegielewska KM, Kuhlenschmidt M, Reilly T and Lee YC: Comparison of N-glycosides of fetuins from different species and human alpha2-HS-glycoprotein. Biochemistry 31: 4915-4921, 1992.
8. Edge AS and Spiro RG. Presence of an O-glycosidically linked hexasaccharide in fetuin. J Biol Chem 262: 16135-16141, 1987.
9. Triffitt JT, Gebauer U, Ashton BA, Owen ME and Reynolds JJ: Origin of plasma α2HS-glycoprotein and its accumulation in bone. Nature 262: 226-227, 1976.
10. Ruminy P, Gangneux C, Claeyssens S, Scotte M, Daveau M and Salier JP: Gene transcription in hepatocytes during the acute phase of a systemic inflammation: from transcription factors to target genes. Inflamm Res 50: 383-390, 2001.
11. Szweras M, Liu D, Partridge EA, Pawling J, Sukhu B, Clokie C, Jahnen-Dechent W, Tenenbaum HC, Swallow CJ, Grynpas MD and Dennis JW: Alpha 2 HS glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression. Cancer Res 64: 6402-6409, 2004.
12. Kalabay L, Jakab L, Prohászka Z, Füst G, Benkö Z, Telegdy L, Lörincz Z, Závodszky P, Arnaud P and Fekete B: Human fetuin/alpha 2 HS glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer. Eur J Gastroenterol Hepatol 14: 389-394, 2002.
13. Kishore BK, Gejyo F and Arakawa M: Alpha 2 HS-glycoprotein in the serum and urine of patients with renal diseases. Postgrad Med J 59: 304-307, 1983.
14. Schinke T, Amendt C, Trindl A, Pöschke O, Müller-Esterl W and Jahnen-Dechent W: The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. J Biol Chem 271: 20789-20796, 1996.
15. Heiss A, DuChesne A, Denecke B, Grötzinger J, Yamamoto K, Renné T and Jahnen-Dechent W: Structural basis of calcification inhibition by alpha2-HS glycoprotein/fetuin-A. J Biol Chem 278: 13333-13341, 2003.
16. Price PA and Lim JE: The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem 278: 22144-22152, 2003.
17. Doherty TM, Fitzpatrick LA, Inoue D, Qiao JH, Fishbein MC, Detrano RC, Shah PK and Rajavashisth TB: Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev 25: 629-672, 2004.
18. Auberger P, Falquerho L, Contreres JO, Pages G, Le Cam G, Rossi B and Le Cam A: Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 58: 631-640, 1989.
19. Rauth G, Poschke O, Fink E, Eulitz M, Tippmer S, Kellerer M, Häring HU, Nawratil P. Haasemann M and Jahnen-Dechent W: The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur J Biochem 204: 523-529, 1992.
20. Srinivas PR, Wagner AS, Reddy LV, Deutsch DD, Leon MA, Goustin AS and Grunberger G: Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 7: 1445-1455, 1993.
21. Mathews ST, Srinivas PR, Leon MA and Grunberger G: Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. Life Sci 61: 1583-1592, 1997.
22. Mathews ST, Chellam N, Srinivas PR, Cintron VJ, Leon MA, Goustin AS and Grunberger G: Alpha 2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol 164: 87-98, 2000.
23. Wang H, Zhang M, Soda K, Sama A and Tracey KJ: Fetuin protects the fetus from TNF. Lancet 350: 861-862, 1997.
24. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Kröber SM, Machicao F, Fritsche A and Häring HU: Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29: 853-857, 2006.
25. Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, Koyama H, Shoji T, Inaba M and Nishizawa Y: Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care 29: 468, 2006.
26. Jahnen-Dechent W, Schinke T, Trindl A, Müller-Esterl W, Sablitzky F, Kaiser S and Blessing M: Cloning and targeted deletion of the mouse fetuin gene. J Biol Chem 272: 31496-31503, 1997.
27. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteier M, Floege J, Muller-Esterl W, Schinke T and Jahnen-Dechent W: The serum protein α2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112: 357-366, 2003.
28. Kuno A, Uchiyama N, Koseki-Kuno S, Ebe Y, Takashima S, Yamada M and Hirabayashi J: Evanescent-field fluorescence-assisted lectin microarray: a new strategy for glycan profiling. Nat Methods 2: 851-856, 2005.
29. Reinehr T and Roth CL: Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab 93: 4479-4485, 2008.
30. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M and Whooley MA: Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 115: 2533-2539, 2007.
31. Okuyama N, Ide Y, Nakano M, et al: Fucosylated haptoglobin is a novel marker for pancreatic cancer. Int J Cancer 118: 2803-2808, 2006.
32. Comunale MA, Lowman M, Long RE, Krakover J, Philip R, Seeholzer S, Evans AA, Hann HW, Block TM and Mehta AS: Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res 5: 308-315, 2006.